MDD US
PharmaMDD US is a pharmaceutical company focused on Neurology. Key products include XADAGO.
MDD US's Key Drugs
MDD US's core commercial portfolio centers on XADAGO, ONAPGO, spanning Neurology — its most strategically important drugs approved in the last 15 years.
MDD US's Recent FDA Approvals
MDD US secured 1 new FDA approval for novel drugs (NDA/BLA) in the last two years.
MDD US's Therapeutic Areas
MDD US's approved drugs and pipeline span 1 therapeutic area, led by Neurology, across 0 biologic and 2 small-molecule drugs. Weighted by commercial stage — approved drugs count most, then late-stage trials.
MDD US's Top Competitors
MDD US's closest competitors by therapeutic-area and drug-target overlap include Pfizer, AbbVie, and Eli Lilly. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
MDD US Pipeline Snapshot
MDD US has 4 active clinical programs from ClinicalTrials.gov — 1 Phase 3, 1 Phase 2 and 2 Phase 1.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • XADAGO leads revenue
- • 2 key drugs tracked
Trial Catalysts
- • Neurology pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Revenue forecasts • Trial milestones • Patent risk modeling